SLN (Silence Therapeutics) Other Operating Expense : $-13.74 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Other Operating Expense?

Silence Therapeutics's Other Operating Expense for the three months ended in Dec. 2024 was $-13.74 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-13.74 Mil.

Silence Therapeutics's quarterly Other Operating Expense declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($-0.00 Mil) and declined from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($-13.74 Mil).

Silence Therapeutics's annual Other Operating Expense declined from Dec. 2022 ($-9.82 Mil) to Dec. 2023 ($-11.95 Mil) and declined from Dec. 2023 ($-11.95 Mil) to Dec. 2024 ($-13.74 Mil).

Silence Therapeutics Other Operating Expense Historical Data

The historical data trend for Silence Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Other Operating Expense Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

4.60

-9.82

-11.95

-13.74

Silence Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-11.95	-	-	-	-13.74

Silence Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.74 Mil.

Silence Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.